|
AU2006252031A1
|
|
Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of SOCS sequences in the animal
|
|
AU2006202060A1
|
|
Purification of vascular endothelial growth factor-B
|
|
AU2005244605A1
|
|
A method of treatment and prophylaxis
|
|
US2004005671A1
|
|
Immunointeractive molecules
|
|
EP1576013A2
|
|
Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13ra1)
|
|
AU2003900437A0
|
|
Immunointeractive molecules
|
|
AU2002950745A0
|
|
A method and agents useful for same
|
|
AUPS130102A0
|
|
Novel peptides
|
|
AU1569702A
|
|
Neocentromere-based mini-chromosomes or artificial chromosomes
|
|
AU2002213668B2
|
|
3-oxadiazol-5-YL-1-aminoalkyl-1H-indole derivatives
|
|
CA2425194A1
|
|
Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal
|
|
AU9351901A
|
|
Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of SOCS sequence in the animal
|
|
AU3711501A
|
|
A method of treatment and prophylaxis
|
|
AU3350101A
|
|
Purification of vascular endothelial growth factor-b
|
|
AU7253900A
|
|
Novel molecules
|
|
AU7253800A
|
|
Novel molecules
|
|
AUPR224700A0
|
|
Neocentromere-based mini-chromosomes or artificial chromosomes
|
|
AUPR194200A0
|
|
A method-ii
|
|
AUPR118000A0
|
|
Therapeutic molecules and methods
|
|
US6911530B1
|
|
Haemopoietin receptor and genetic sequences encoding same
|
